Sarepta Shares Early SiRNA Clinical Data; Stock Up

Sarepta reported first clinical results from two investigational siRNA programs, showing high muscle drug concentrations and favorable tolerability in early-stage studies. The readouts cover programs targeting facioscapulohumeral muscular dystrophy type 1 (FSHD1) and a myotonic indication (article text truncated); findings are preliminary and will need further clinical validation.

Analysis

Sarepta reported first clinical results from two investigational siRNA programs, showing high muscle drug concentrations and favorable tolerability in early-stage studies. The readouts cover programs targeting facioscapulohumeral muscular dystrophy type 1 (FSHD1) and a myotonic indication (article text truncated); findings are preliminary and will need further clinical validation.